Clinical trial
A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and…
NCT00349531 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00349531 |
|---|---|
| Title | A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS |
| Official title | A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Pramipexole |
| Enrollment | 369 |
| Start date | Jul 1, 2006 |
| Primary completion | May 1, 2007 |
| First posted | Jul 7, 2006 |
| Last update posted | May 21, 2012 |
| Countries | Denmark, Finland, Germany, Ireland, Italy, Norway, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: